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Abstract 
Rationale: In the endothelium, insulin stimulates endothelial nitric oxide synthase (eNOS) to 
generate the anti-atherosclerotic signalling radical NO. Insulin resistant type 2 diabetes is 
associated with reduced NO availability and accelerated atherosclerosis. The effect of 
enhancing endothelial insulin sensitivity on NO availability is unclear.  
Objective: To answer this question we generated a mouse with endothelial cell (EC)-specific 
over-expression of the human insulin receptor (hIRECO) using the Tie2 promoter-enhancer.  
Methods and Results: hIRECO demonstrated significant endothelial dysfunction measured 
by blunted endothelium-dependent vasorelaxation to acetylcholine which was normalized by 
a specific Nox2 NADPH oxidase inhibitor. Insulin-stimulated phosphorylation of Akt was 
increased in hIRECO EC as was Nox2 NADPH oxidase-dependent generation of superoxide, 
whereas insulin and shear stress-stimulated eNOS activation were blunted. Phosphorylation 
at the inhibitory residue Y657 of eNOS and expression of PYK2 which phosphorylates this 
residue were significantly higher in hIRECO EC. Inhibition of PYK2 improved insulin and 
shear-induced eNOS activation in hIRECO EC.  
Conclusions: Enhancing insulin sensitivity specifically in EC leads to a paradoxical decline 
in endothelial function, mediated by increased tyrosine phosphorylation of eNOS and excess 
Nox2 derived superoxide. Increased EC insulin sensitivity leads to a pro-atherosclerotic 
imbalance between NO and superoxide. Inhibition of PYK2 restores insulin- and shear-
induced NO production. This study demonstrates for the first time that increased endothelial 
insulin sensitivity leads to a pro-atherosclerotic imbalance between NO and superoxide. 
 
Key Words: Insulin; Insulin Resistance; Endothelial Dysfunction; PYK2; Reactive oxygen 
Species; Superoxide 
 
Non-standard Abbreviations and Acronyms: NO-nitric oxide, hIR-human Insulin 
Receptor; hIRECO- endothelial cell (EC)-specific over-expression of the human insulin 
receptor; EC-endothelial cells; PEC-pulmonary endothelial cells; PYK2-proline-rich tyrosine 
kinase 2; Akt-protein kinase B; ACh-acetylcholine; PE-phenylephrine; SNP-sodium 
nitroprusside; eNOS-endothelial nitric oxide synthase. 
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Introduction 
Recent changes in human lifestyle have led to a global epidemic of type 2 diabetes mellitus.1 
Type 2 diabetes mellitus is characterized by hyperinsulinaemic insulin resistance,2 a situation 
whereby insulin is unable to activate its intricate intracellular signalling network in an 
appropriate temporospatial fashion.3 Insulin resistance results in a loss of protection against 
a range of chronic disorders of human health, principal amongst which is atherosclerosis.4 A 
key step in the initiation and progression of atherosclerosis is the deleterious change in 
endothelial cell phenotype, characterised by an imbalance between the anti-atherosclerotic 
signalling radical nitric oxide (NO) and generation of the potentially cytotoxic free radical 
superoxide, a scenario described as endothelial dysfunction.5  
There is a compelling body of evidence from studies in endothelial cells in vitro demonstrating 
that insulin, by acting on its tyrosine kinase receptor, stimulates production of NO,6 inhibits 
superoxide generation, blunts inflammatory cell recruitment and inhibits thrombosis.7 In vivo 
models of insulin resistance at a whole body level,8 and at the level of the endothelium,9,10 
have confirmed the hypothesis that insulin resistance per se leads to a reduced level of NO, 
excessive generation of superoxide and accelerated atherosclerosis.  
While we appreciate the effects of whole body and cell-specific insulin resistance on the 
development of atherosclerosis, the local and systemic consequences of prolonged insulin 
signalling in the endothelium are poorly understood. Therefore, in order to improve our 
mechanistic understanding of the impact of selectively enhancing insulin action in the 
endothelium on the development of atherosclerosis, from its earliest biochemical 
manifestation of reduced NO availability, to lipid deposition and structural changes in the 
arterial wall, we have generated a transgenic mouse model over-expressing the human 
insulin receptor (IR) specifically in the endothelium. For the first time, we demonstrate that 
endothelial cell over-expression of IR enhances insulin-stimulated activation of the kinase 
Akt, which increases activity of the superoxide generating enzyme Nox2 NADPH oxidase. 
Additionally, over-expression of IR also increases expression of proline rich tyrosine kinase 
(PYK2), a negative regulator of endothelial NO synthase (eNOS).11 In the presence of 
enhanced insulin signalling, crosstalk between Nox2 and PYK2 increases their expression 
further, thus amplifying the deleterious effect of prolonged enhancement of endothelial cell 
insulin signalling on the critical balance between NO and superoxide levels. Taking these 
findings further, we crossed transgenic mice with endothelium-specific expression of the IR 
onto an atherosclerosis-prone apolipoprotein E deficient background. Interestingly, these 
mice developed accelerated atherosclerosis. Our findings demonstrate that enhanced and 
prolonged insulin signalling specifically in the endothelium, establishes a deleterious feed-
forward circuit involving: IR, Akt, Nox2, PYK2 and eNOS, leading to endothelial dysfunction 
and accelerated atherosclerosis. 
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Methods 
Mice over-expressing the human insulin receptor specific to the endothelium. To 
examine the local and systemic consequences of prolonged enhancement of insulin 
sensitivity in the endothelium we generated a transgenic mouse with endothelium specific 
over expression of the type A isoform of the human IR (Supplemental Figure IA). Mice were 
bred onto a C57BL/6J background to at least 10 generations in a conventional animal facility 
with a 12-h light/dark cycle. Male mice aged 3-4 months were used in all experiments, which 
were conducted in accordance with accepted ethical standards of humane animal care (UK 
Animals Scientific Procedure Act 1986) under United Kingdom Home Office Project License 
No. 40/2988.  
To overcome the limitations seen in standard transgenics we used the Hypoxanthine 
Phophoribosyl transferase (Hprt) targeting system that we have used previously12 applying 
‘Quick Knock-inTM’ (GenOway) technology to generate genetically modified embryonic stem 
(ES) cells. This approach uses homologous recombination to target a single copy of a 
transgene (in this case the human IR) driven by a promoter (in this case the Tie2 promoter) 
into the Hprt locus on the X chromosome. 
 
As previously described,13 the model was developed with E15Tg2a (E14) cells derived from 
the strain 129P2/OiaHsd (12901a). Tissue-specific promoters including Tie214 inserted into 
the Hprt locus maintain their expression properties.  For detailed methods, see Supplemental 
Materials online. 
 
Myeloid cell enumeration, isolation and transcriptional profiling 
Peripheral blood mononuclear cells (PBMC) were isolated using density gradient 
centrifugation (Histopaque 1083; Sigma) of heparinised venous blood collected during 
terminal anaesthesia. 2x105 PBMC were used for labelling with an APC-conjugated CD11b 
antibody (AbD Serotec) or APC-conjugated isotype control, after blocking non-specific 
antibody binding with Fc receptor block (BD Biosciences). Monocytes were enumerated using 
an LSR-Fortessa cytometer (BD Biosciences) based on either typical light scatter properties, 
or separately based on CD11b expression, with normalisation to total mononuclear cell count 
(Supplemental Figure IA to IF). Remaining PBMC were incubated with CD11b microbeads 
(Miltenyi Biotec) prior to undergoing 2 rounds of magnetic purification using MS-columns 
(Miltenyi Biotec), achieving purity exceeding 90%. CD11b+ cells were immediately lysed 
using TRIzol reagent (Life Technologies), then total RNA isolated according the 
manufacturer’s protocol. RNA was then cleaned (RNeasy MinElute; Qiagen), amplified and 
reverse transcribed to cDNA (QuantiTect; Qiagen), prior to qRT-PCR (LightCycler; Roche) 
using validated TaqMan probes (Life Technologies) for murine TNF-α, murine IL-1β, murine 
IL-6, and human Insulin receptor. All expression was normalised to the cycle threshold of 
murine β-actin using the 2-ΔCT method. Human umbilical vein endothelial cells and HIRECO 
lung endothelial cells served as positive controls for human insulin receptor qRT-PCR. 
 
Metabolic tests and plasma circulating levels of insulin, TNF alpha, IL6 and nitrite. 
Blood was sampled from the lateral saphenous vein. Glucose and insulin tolerance tests were 
performed by blood sampling after an intraperitoneal (IP) injection of glucose (Sigma, 1mg/g) 
or human recombinant insulin (0.75 unit/kg: Actrapid; Novo Nordisk, Bagsvaerd, Denmark) 
as previously described15. Glucose concentrations were determined in whole blood by a 
portable glucometer (Roche Diagnostics, 2 Burgess Hill, UK). Plasma insulin concentrations 
were determined by enzyme-linked immunoassay (Ultrasensitive mouse ELISA; 
CrystalChem, Downers Grove, IL, USA). Free fatty acids and triglycerides were measured in 
fasting plasma using colorimetric assays (AbCam). Plasma levels of TNF alpha, IL6 and 
nitrite were measured using colorimetric assays (AbCam). 
 
In vivo blood pressure measurement. Systolic blood pressure was measured using tail-
cuff plethysmography in conscious mice, as previously described.15,16 Mice were pre-warmed 
 5 
for 10 minutes in a thermostatically controlled restrainer (CODA2 System, XBP1000; Kent 
Scientific). Three training sessions were performed during the week before measurements 
were taken. The mean of at least five separate recordings on three occasions was taken to 
calculate mean systolic blood pressure.  
 
Studies of vasomotor function in aortic rings. Vasomotor function was assessed ex-vivo 
in aortic rings as previously described.15-17 Rings were mounted in an organ bath containing 
Krebs Henseleit buffer (composition [in mmol/L]: NaCl 119, KCl 4.7, KH2PO4 1.18, NaHCO3 
25, MgSO4 1.19, CaCl2 2.5, and glucose 11.0) gassed with 95% O2/5% CO2. Rings were 
equilibrated at a resting tension of 3g for 45min before the experiments. A cumulative dose-
response to the constrictor phenylephrine (PE) (1nmol/L to 10mol/L) was first performed. 
Relaxation responses to cumulative addition of acetylcholine (ACh) (1nmol/L-10µmol/l) and 
sodium nitroprusside (SNP) (0.1nmol/L-1µmol/l) were carried out. Insulin mediated 
vasorelaxation was assessed in 2 different ways: 1) direct vasorelaxation responses in 
response to incremental doses of Actrapid insulin (0.1-4mU/ml) in aortic segments pre-
constricted maximally with PE. 2) Examining the effect of insulin to reduce PE mediated 
vasoconstriction as we previously reported.18 Relaxation responses are expressed as 
percentage decrement in pre-constricted tension. Bioavailable NO in aortic segments 
subjected to isometric tension was measured by recording the change in tension elicited by 
the non-selective endothelial NOS inhibitor, L-NMMA (0.1mmol/L) in aortic segments pre-
constricted maximally with PE. (Percentage change calculated as percentage change from 
maximal constriction to PE after L-NMMA18). The effects of gp91ds-tat (50 μmol/L for 30 min, 
GenScript) and MnTmPyP (10 μmol/L for 30 min, Calbiochem) on aortic relaxation were 
examined, as previously reported.15  
 
Nitric oxide synthase activity in endothelial cells. Upon activation, eNOS produces NO 
and L-citrulline in a stoichiometric reaction. The effect of insulin on eNOS activity in 
endothelial cells was determined by conversion of [14C]-L-arginine to [14C]-L-citrulline as we 
previously described.12 Endothelial cells (1 x 106 cells) were incubated at 37°C for 20 min in 
HEPES buffer pH 7.4 (in mmol/L): 10 HEPES, 145 NaCl, 5 KCl, 1 MgSO4, 10 glucose, 1.5 
CaCl2 containing 0.25% BSA. 0.5 μCi/ml L-[14C] arginine (Amersham) was then added for 5 
minutes and tissues stimulated with insulin (150nmol/L) for 45 min before the reaction was 
stopped with cold phosphate-buffered saline (PBS) containing 5 mmol/L L-arginine (Sigma 
Aldrich) and 4 mmol/L EDTA after which tissue was denatured in 95% ethanol. After 
evaporation, the soluble cellular components were dissolved in 20mmol/L HEPES-Na+ (pH 
5.5) and applied to a well-equilibrated DOWEX (Na+-form) column (Sigma Aldrich). The L-
[14C] citrulline content of the eluate was quantified by liquid scintillation counting and 
normalized against the total cellular protein used.  
 
Immunoprecipitation of phosphorylated insulin receptor. Tyrosine phosphorylation of 
Insulin Receptor was quantified using Western blotting.17 Immunoprecipitation of protein for 
the quantification of receptors was achieved by incubating equal amounts of protein lysates 
(50 µg) and 50 µL of protein A-DynaBeads (Invitrogen) pre-coated with indicated rabbit anti-
insulin receptor antibody for 20 minutes. After 3 rounds of washing with PBS-0.01%Tween-
20, the beads were resuspended in 2x Laemmli loading buffer supplied with the NOVEX Gel 
Electrophoresis system. Cellular protein was separated by SDS-PAGE and blots were probed 
with a mouse Phospho-tyrosine 4G10 (Millipore), IR-beta (C-19) antibodies for receptor 
expression (Santa Cruz Biotechnologies). This experiment was performed after overnight 
serum-deprivation. Since basal levels would be decreased during this period, insulin-induced 
tyrosine phosphorylation of insulin receptor has been quantified and compared to vehicle 
control. 
 
Cell lysis, Immunoblotting. Primary endothelial cells were cultured in 20% FCS-containing 
media for analysing basal protein levels. Cells were lysed in extraction buffer containing 
50mM HEPES, 120mM NaCl, 1mM MgCl2, 1mM CaCl2, 10mM NaP2O7, 20mM NaF, 1mM 
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EDTA, 10% glycerol, 1% NP40, 2mM sodium orthovanadate, 0.5µg/ml leupeptin, 0.2mM 
PMSF, and 0.5µg/ml aprotinin. Insulin-stimulated endothelial cells were serum-deprived 
overnight with 1% FCS-containing endothelial cell media before stimulation and harvesting 
in lysis buffer for western blot analysis. Cell extracts were sonicated in an ice-bath and 
centrifuged for 15 minutes at 13000 rpm, before protein measurements were carried out by 
BCA assay (Pierce Protein Quantification Kit) using the supernatant. Equal amounts of 
cellular protein were resolved on SDS polyacrylamide gels (Invitrogen) and transferred to 
polyvinylidine difluoride membranes and immunoblotted with appropriate antibodies (for 
details see Supplemental Material). The assays are run on the same blot for both wild type 
and transgenic mice, whenever possible to fit all experimental conditions onto one gel, 
thereby negating issues with exposure time. Our approach using the Syngene densitometry 
(Syngene Gel Documentation) system also avoids issues with exposure time and blotting 
efficiency. Wherever stimulation has been carried out after overnight serum-deprivation, the 
result has been calculated as percentage of vehicle control. 
 
Assessment of superoxide generation 
Lucigenin enhanced chemiluminescence. We used lucigenin (5μmol/L)-enhanced 
chemiluminescence to measure NAD(P)H-dependent superoxide production in pulmonary 
endothelial cells, as previously described.9 All experiments were performed in triplicate. 
Pulmonary endothelial cell monolayer was trypsinized and re-suspended in PBS containing 
5% FCS, 0.5% BSA and 50umol/L gp91ds-tat (gptat; GenScript) or scrambled peptide (Scr; 
GenScript) and incubated at 37˚C for 30 min. Luminescence was then measured upon 
addition of a non-redox cycling concentration of lucigenin (5µM) and NADPH (100µmol/L), 
using an autodispenser (VarioSkan 96-well microplate luminometer, Thermo Scientific). 
Wortmannin (WM; 50 nanomol/L, Calbiochem) and LY294002 (LY; 25nmol/L, Calbiochem) 
was used to inhibit PI3-kinase and MK-2206 (MK; 10 micromol/L, Calbiochem) to inhibit Akt 
in pulmonary endothelial cells to study the role of PI3-kinase and Akt in NADPH oxidase-
induced superoxide production. Where wortmannin, LY294002 or MK-2206 were used for 
the measurement of reactive oxygen species production, endothelial cell suspension was 
prepared from both wild type and hIRECO mice in equal cell concentration. The inhibitors 
were incubated for 30 minutes before measuring free radical generation. Data presented as 
percent decrease against non-inhibited cells.  
 
High performance liquid chromatographic measurement of conversion of 
dihydroethidium to oxyethidium. In order to measure Nox2 dependent aortic superoxide 
production, we used high performance liquid chromatography (HPLC)-based detection of the 
oxidation products of dihydroethidium (DHE, Invitrogen), i.e. 2-hydroxyethidine (EOH) and 
ethidium (E), as previously described25 in aortic rings from hIRECO and wild type mice 
exposed to the nox2 inhibitor gp91dstat (for detailed methods, see Supplemental Material). 
 
Amplex red assay for hydrogen peroxide in aorta. H2O2, the downstream dismutation 
product of superoxide, was measured using an Amplex® Red Hydrogen 
Peroxide/Peroxidase Assay Kit (Molecular Probes, Life Technologies) according to the 
manufacturer’s protocol (for detailed methods, see Supplemental Material). 
 
Gene expression. mRNA was isolated using a commercial kit (Sigma Aldrich), and the levels 
of eNOS, Nox2, Nox4, SOD, catalase, ve-cadherin, IL6, TNF alpha and IR mRNA quantified 
using real-time quantitative PCR (SYBR Green-based or Taqman Probe assay in AB 
Systems 7900HT machine (Supplemental Table 1)15. A range of housekeeping genes were 
screened for variability and stability. Non-specific primers and those specific for human and 
mouse IR were designed and validated in human umbilical vein endothelial cells and mouse 
pulmonary endothelial cells (Supplemental Table I).  
 
Endothelial cell isolation and culture. Primary endothelial cells were isolated from lungs 
by immunoselection (Supplemental Figure IIIB) with CD146-antibody-coated magnetic beads 
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(Miltenyi Biotechnology) as previously reported.17 (for detailed methods, see Supplemental 
Material) 
 
Exposure of endothelial cells to flow-mediated shear stress. Pulmonary endothelial cells 
were seeded onto fibronectin-coated 6-well plates. Once confluent, monolayers were placed 
onto an orbital rotating platform (Grant Instruments) housed inside the incubator.19 The radius 
of orbit of the orbital shaker was 10mm and the rotation rate was set to 210rpm for 10 minutes, 
which caused swirling of the culture medium over the cell surface volume. The movement of 
fluid due to orbital motion represents a free surface flow at the liquid-air interface at 12 
dyne/cm2.  
 
Chronic pharmacological inhibition of NADPH oxidase. To examine the effect of inhibition 
of Nox2 NADPH oxidase on endothelial cell function in hIRECO mice, we performed chronic 
treatment studies using the peptiditic Nox2 inhibitor, gp91ds-tat. hIRECO mice were 
anesthetised and osmotic mini-pumps (Alzet 2004) containing gp91ds-tat or control 
scrambled peptide implanted, as previously reported.15 The pump delivered 0.25uL of drug 
per hour for 28 days. The concentration of the scrambled and gp91ds-tat peptide was 
adjusted (50mg/ml) to deliver 10mg/kg/day. Animals were sacrificed after 28 days and organ 
bath experiments were carried out to assess vasomotor function. 
 
siRNA-mediated knockdown of Nox2 NADPH oxidase and proline-rich tyrosine kinase. 
Silencing of PYK2 and Nox2 NADPH oxidase gene expression in pulmonary endothelial cells 
was carried out by transfection of mouse siRNA duplexes (Stealth RNAi, Invitrogen) with 
Lipofectamine RNAiMax Transfection Reagent (Invitrogen) exactly according to 
manufacturer’s established protocol and as we previously, reported.15 Scrambled siRNA was 
used as negative control (Invitrogen) for transfection. Briefly, isolated pulmonary endothelial 
cells from lung tissues were rendered 70% confluent and transfected with 25pmol siRNA for 
72 hours before cell lysates were prepared for quantitative RT-PCR and western blotting 
analysis.  
 
Quantification and characterisation of atherosclerosis. In order to study the effects of 
endothelial IR over-expression on the development of atherosclerosis, we crossbred hIRECO 
mice with mice holoinsufficient for ApoE (ApoE-/-). Mice (ApoE-/- and ApoE-/-/hIRECO) were 
fed a western diet (21% fat from lard supplemented with 0.15% wt/wt cholesterol, #829100, 
SDS, Witham, Essex, UK) for 12 weeks from 4 weeks of age to induce atherosclerosis.20 
Mice were surgically anaesthetised by intraperitoneal injection of sodium pentobarbitone 
before thorough terminal exsanguination by arterial perfusion via the abdominal aorta with 
PBS at a constant pressure of 100mmHg with outflow through the severed jugular veins. This 
was followed by constant pressure perfusion in-situ with 10% formalin. The heart was 
removed to study the aortic sinus. In other animals, the thoracic and abdominal aorta was 
dissected to allow en face quantification of plaque development.  
 
Plaque quantification in en face sections of aorta. For en face analysis, aortas were 
analysed, as previously described.16,20 Briefly, aortas were removed, fixed in PBS-buffered 
4% formalin, cut longitudinally, stained with Oil Red O, and photographed (Olympus digital 
camera QICAM) under dissection microscope (Olympus SZ61). Percentage coverage of 
plaque area was measured using Image-Pro Plus 6.0 (Media Cybernetic, Bethesda, MD) 
software. 
 
Statistics. Results are expressed as mean±SEM. Comparisons within groups were made 
using paired Student’s t-tests and between groups using unpaired Student’s t tests, as 
appropriate; where repeated t-tests were performed a Bonferroni correction was applied. 
P<0.05 was considered statistically significant. 
 
 
 8 
Results 
Generation and characterisation of transgenic mice over-expressing the human 
insulin receptor in the endothelium. To examine the effect of enhancing insulin sensitivity 
in the endothelium, we generated a novel transgenic mouse over-expressing the human type 
A insulin receptor directed to the endothelium under control of the Tie2 promoter-enhancer 
(henceforth, described as human insulin receptor endothelial cell over expressing mice, 
hIRECO, Supplemental Figure IA-D). hIRECO were born with the same frequency as wild 
type littermates, and there was no difference in growth (Figure 1A, left) or organ weight, 
measured at 12 weeks of age (Figure 1A, right) between hIRECO and wild type littermates 
(WT). We quantified levels of human and native (mouse) insulin receptor (IR) mRNA 
expression in organs with differing vascularity (heart, lung, spleen). Human IR mRNA 
expression in hIRECO recapitulated the pattern for native IR seen in wild type mice (Figure 
1B). There was no difference in mRNA expression of endogenous insulin receptor between 
hIRECO and wild type (Figure 1C). There was no human IR mRNA detectable in endothelial 
cells from wild type mice or non-endothelial cells from hIRECO (Figure 1D). Non-endothelial 
cells did not express the endothelial-specific marker, ve-cadherin in contrast to endothelial 
cells (Figure 1E). mRNA expression of mouse IR also remained unchanged in the isolated 
EC (Figure 1F). Total IR protein expression was significantly increased in hIRECO endothelial 
cells compared to wild-type littermates (Figure 1G). Some studies have suggested that the 
Tie2 promoter-enhancer drives the expression in myeloid cells.21 In order to examine this 
possibility, we isolated circulating CD11b+ myeloid cells from hIRECO and wild type 
littermates, as previously described.22 There was no difference in total circulating CD11b+ or 
monocyte count (Supplemental Figure IIA-C), gene expression of TNF-alpha, IL-1beta and 
IL-6 in hIRECO CD11b+ cells (Supplemental Figure IID-F) or concentrations of the circulating 
inflammatory cytokines TNF-alpha and IL-6 in hIRECO (Supplemental Figure IIIC and D) 
compared to wild type littermates. We could not detect human IR mRNA in monocytes from 
hIRECO.  
 
Enhanced endothelial cell insulin sensitivity in hIRECO mice. Consistent with enhanced 
insulin action at the insulin receptor signalling node, basal and insulin-stimulated levels of 
tyrosine phosphorylated IR were substantially higher in endothelial cells from hIRECO 
compared to their wild type littermates (Figure 2A). Basal serine-473 phosphorylation of Akt 
in endothelial cells from hIRECO was markedly enhanced (Figure 2B, right) as was basal 
eNOS serine-1177 (Figure 2B, left). In dose-response experiments, Akt phosphorylation in 
response to insulin was also significantly enhanced in hIRECO endothelial cells (Figure 2C). 
 
hIRECO mice have normal glucose tolerance and blood pressure and elevated plasma 
nitrite. Over-expression of the IR in the endothelium had no effect on fasting glucose, (Figure 
3A) fasting insulin levels (Figure 3B) or blood pressure levels at the age of 3 months (Figure 
3C). hIRECO had similar responses in glucose tolerance tests (Figure 3D) and insulin 
tolerance tests (Figure 3E) to wild type littermates. Plasma triglycerides (Figure 3F) and free 
fatty acid levels (Figure 3G) were not different between hIRECO and wild type littermates. 
Consistent with increased basal eNOS serine phosphorylation, plasma nitrite was also 
increased (Supplemental Figure IIIE). 
 
hIRECO mice have reduced NO availability. We examined the effect of excessive insulin 
signalling on aortic vasomotor responses in an organ bath. Aortic rings from hIRECO mice 
had blunted responses to the endothelium- and NO-dependent vasodilator, acetylcholine 
(ACh, Figure 4A). Vasoconstriction to phenylephrine (PE) remained unchanged in hIRECO 
compared to wild type littermates (Figure 4B), as did vasorelaxation in response to the 
endothelium-independent vasodilator sodium nitroprusside (SNP, Figure 4C). Basal NO 
production in response to isometric tension assessed by measuring the constrictor response 
to the NO synthase inhibitor L-NMMA was reduced in hIRECO mice (Figure 4D, 
Supplemental Figure IV B). In aortic rings from hIRECO animals we assessed insulin-
mediated NO-dependent vasorelaxation followed by 2 methods. Insulin pre-treatment blunts 
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phenylephrine-induced vasoconstriction in an NO- and endothelium-dependent fashion.18 We 
demonstrated that this vasodilatory response to insulin was blunted in hIRECO mice aortae 
(Figure 4E), as was acute vasorelaxation of phenylephrine pre-constricted aortic rings in 
response to varying doses of insulin (Figure 4F; left). Moreover, L-NMMA significantly blunted 
insulin-mediated vasodilatation (Figure 4F; right), demonstrating that insulin-mediated 
vasodilation is NO-dependent. There was also a significant reduction in eNOS activity in 
response to insulin in hIRECO endothelial cells compared to endothelial cells from wild type 
littermates (Figure 4G). Therefore, increased expression of the insulin receptor in the 
endothelium leads to resistance to insulin downstream of Akt. In response to chemical cues 
(e.g. insulin) and mechanical stimuli (e.g. shear stress), Akt is activated leading to serine-
1177 phosphorylation of eNOS to stimulate generation of NO.23,24 Therefore, we assessed if 
phosphorylation of Akt and eNOS were impaired in the hIRECO endothelial cells; leading to 
decreased NO and vasodilation observed in these hIRECO mice. We demonstrated that 
shear stress-mediated serine phosphorylation of Akt was similar between both groups of mice 
(Figure 4H). Interestingly, shear stress-mediated serine phosphorylation of eNOS (Figure 4I) 
was blunted in hIRECO when compared to wild type littermates.  
 
Nox2 NADPH oxidase and excess superoxide in hIRECO mice. Decreased endothelium-
dependent vasorelaxation and reduced NO bioavailability could be mediated by increased 
superoxide generation.15 In order to examine the possibility that the underlying mechanism 
of the blunted acetylcholine responses in hIRECO mice is at least, in part due to excess 
superoxide, we exposed aortic rings from hIRECO to the superoxide dismutase mimetic, 
Mn(III) tetrakis (1-methyl-4-pyrydil) porphyrin pentachloride (MnTmPyP) before performing 
dose-response studies to acetylcholine (Figure 5A). Consistent with excessive generation of 
superoxide, the maximal relaxation of rings from hIRECO mice in response to acetylcholine 
in the presence of MnTmPyP was significantly restored to normal wild type level. We have 
previously demonstrated that mice with whole body8 and endothelium-specific insulin 
resistance15 have excess generation of superoxide as a result of increased Nox2 NADPH 
oxidase activity. In order to examine the possibility of this underlying mechanism in mice with 
enhanced endothelial insulin signalling, we treated aortic rings from hIRECO mice with 
gp91ds-tat, a Nox2 specific NADPH oxidase inhibitor and assessed the response to 
acetylcholine. Consistent with this hypothesis, gp91ds-tat significantly increased the maximal 
response to acetylcholine of aortae from hIRECO mice (Figure 5B). We investigated the role 
of superoxide in endothelial function by direct measurement of superoxide release in isolated 
endothelial cells, using NADPH-dependent lucigenin-enhanced chemiluminescence assay, 
confirming the effects seen the organ bath studies. hIRECO endothelial cells demonstrated 
a 1.5-fold increase in superoxide release (Figure 5C). This finding was associated with a 
significant increase in Nox2 protein expression (Figure 5D) in hIRECO endothelial cells. The 
basal increase in superoxide production in hIRECO endothelial cells was reduced to wild type 
levels, in the presence of gp91ds-tat (Figure 5E, left) as well as in hIRECO aorta measured 
using HPLC (Figure 5E, centre) indicating that Nox2 NADPH oxidase was the principal 
source of the excess superoxide. Amplex Red quantification of hydrogen peroxide 
demonstrated marked increase in hydrogen peroxide release in hIRECO endothelial cells 
(Figure 5E, right). To examine further the effect of chronic pharmacological inhibition of Nox2 
NADPH oxidase, we administered gp91ds-tat to hIRECO mice via osmotic mini-pump for 28 
days, as we described recently.15 Chronic treatment with gp91ds-tat had no effect on body 
mass (Figure 5F), organ weight (Supplemental Figure IV A), glucose (Figure 5G:left) and 
insulin tolerance tests in hIRECO mice (Figure 5G:centre). To examine the effect of chronic 
in vivo pharmacological inhibition of NADPH oxidase on endothelium-dependent vasomotor 
responses, we studied aortic rings from hIRECO mice after treatment with gp91ds-tat or 
scrambled peptide to examine acetylcholine-induced vasorelaxation ex vivo. Gp91ds-tat 
significantly enhanced (albeit to a small extent) maximal acetylcholine-induced aortic 
relaxation compared to scrambled peptide (Figure 5H). Chronic treatment with gp91ds-tat 
had no effect on SNP-mediated vasorelaxation in hIRECO (data not shown) indicative of 
preservation of responses in vascular smooth muscle.  
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In order to determine whether the negative effects of excessive endothelial insulin signalling 
is a consequence of alteration of expression of various protective or compensatory 
antioxidant enzymes, quantitative real-time polymerase chain reaction experiments were 
performed in endothelial cells. hIRECO mice had no difference in expression of superoxide 
dismutase (SOD) 1, SOD2, SOD3, or catalase. (Supplemental Figure IIIA). 
 
Insulin-stimulated superoxide generation in hIRECO mice. We next examined the 
involvement of the critical signalling node PI3-kinase in generation of the excessive  
superoxide release seen in hIRECO mice using the PI3-kinase inhibitors, Wortmannin and 
LY294002.26 Wortmannin inhibited NADPH-dependent superoxide production assessed 
using lucigenin-enhanced chemiluminescence (Figure 6A), as did an alternative PI3-kinase 
inhibitor LY294002 (Figure 6B), demonstrating that the PI3-kinase signalling node is 
potentially important for the increased endothelial superoxide production in hIRECO mice. 
Previous studies have suggested that downstream of PI3-kinase increased Akt activation 
may lead to increased oxidative stress.27,28 Since we found that hIRECO had increased Akt 
activation, we treated hIRECO endothelial cells with the allosteric Akt inhibitor, MK-2206.29 
MK-2206 reduced superoxide generation from hIRECO endothelial cells (Figure 6C). We 
examined further, whether insulin-stimulated superoxide generation in endothelial cells from 
hIRECO is mediated via AKT and Nox2 activation. Therefore, we assessed the effects of Akt 
and Nox2 blockers, MK-2206 or gp91ds-tat, respectively. Insulin did not stimulate a 
detectable increase in superoxide in wild type endothelial cells. Insulin, however did stimulate 
an increase in superoxide production in hIRECO endothelial cells (Figure 6D). This excess 
generation of superoxide in response to insulin was blunted by the Akt inhibitor MK-2206 
(Figure 6D) and the Nox2 inhibitor gp91ds-tat (Figure 6D) demonstrating that the insulin-
stimulated increment in superoxide was Akt and Nox2 dependent.  
 
Role of eNOS tyrosine phosphorylation in endothelial dysfunction in hIRECO mice. 
Previous studies have demonstrated that insulin, by increasing the expression of proline rich 
tyrosine kinase 2 (PYK2), may lead to phosphorylation of eNOS on tyrosine residues which 
inhibit eNOS activity.11 To examine this possibility, we measured levels of tyrosine-657 
phosphorylated eNOS in endothelial cells from hIRECO. We found that phosphorylation of 
the inhibitory residue Tyr657 was significantly increased in hIRECO compared to wild type 
littermates (Figure 6E, left) and inhibition of NOX2 by gp91ds-tat significantly reversed this 
effect (Figure 6E, right). Moreover, expression of PYK2 was also increased (Figure 6F) and 
the expression of phosphorylated PYK2 was similar when comparing hIRECO to wild type 
littermates (data not shown). To further examine the role of PYK2 in endothelial dysfunction 
in hIRECO using siRNA in isolated endothelial cells, we reduced PYK2 expression by 
approximately 50 percent (Figure 6G). In siRNA treated cells, we assessed eNOS activity 
and performed the L-arginine to L-citrulline conversion assay in the presence of insulin and 
eNOS phosphorylation in response to shear stress. Both insulin-stimulated eNOS activity 
(Figure 6H) and shear stress-mediated eNOS serine-phosphorylation (Figure 6I) were 
significantly increased in hIRECO cells with reduced PYK2. 
 
Examining crosstalk between Nox2 and PYK2. In order to examine the possibility of 
crosstalk between Nox2 and PYK2, we performed siRNA experiments knocking down either 
Nox2 or PYK2. These experiments revealed an intriguing, yet previously unrecognised feed-
forward loop. Chronic reduction of Nox2 activity with gp91 ds-tat and inhibiting Akt with MK-
2206 reduced PYK2 expression in the hIRECO endothelial cells (Figure 7A). MK-2206 and 
gp91ds-tat reduced PYK2 expression revealing a new signalling circuit linked to enhanced 
insulin signalling including Akt, Nox2 and PYK2 which conspire to reduce basal and 
stimulated NO bioactivity. To further examine this interaction in hIRECO mice, we used 
siRNA to knockdown Nox2; this led to reduced PYK2 expression (Figure 7B), indicative of 
superoxide-mediated regulation of PYK2 expression in hIRECO mice. Knockdown of PYK2 
in hIRECO endothelial cells with siRNA significantly reduced NOX2 expression (Figure 7C) 
and also improved eNOS phosphorylation in the presence of insulin (Figure 7D). However, 
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knockdown of NOX2 failed to reverse the decrease in insulin-stimulated eNOS 
phosphorylation (Figure 7D), suggesting that the reduction of insulin-stimulated eNOS 
phosphorylation is mediated via increases in PYK2 activity and not directly through Nox2 
activation.  
 
Over-expression of insulin receptor in the endothelium leads to accelerated 
atherosclerosis. In order to examine the effect of over-expression of insulin receptor in the 
endothelium on the development of advanced atherosclerosis, we crossed pro-atherogenic 
ApoE-/- mice with hIRECO to generate ApoE-/-/hIRECO. ApoE-/-/hIRECO and ApoE-/- 
littermates were fed a high cholesterol western diet for 12 weeks from 8 weeks of age. After 
12 weeks feeding, body weights were similar in ApoE-/-/hIRECO and ApoE-/- littermates 
(Figure 8A). Systolic blood pressure (Figure 8B), plasma cholesterol (Figure 8C) and 
triglyceride levels (Figure 8D) were no different in ApoE-/-/hIRECO compared to ApoE-/-. 
Fasting glucose (Figure 8E) was similar between ApoE-/-/hIRECO and ApoE-/-. Glucose 
homeostasis assessed in glucose tolerance (Figure 8F) and insulin tolerance tests were 
comparable between ApoE-/-/hIRECO and ApoE-/- (Figure 8G). In contrast, ApoE-/-/hIRECO 
demonstrated a significant increase in the development of atherosclerosis in the whole aorta 
(Figure 8H) and also at the level of the aortic sinus (Figure 8I). We describe here a novel 
proatherosclerotic signalling loop whereby increased endothelial cell insulin sensitivity leads 
to overactivation of NOX2, generating excess superoxide anion and thereby, decreasing nitric 
oxide availability.  Activation of NOX2 in turn, leads to increased PYK2 expression and eNOS 
tyrosine phosphorylation. This effect leads to a further decrease in NO availability and 
enhanced atherogenesis (Figure 8J).  
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Discussion 
Despite intensive efforts to prevent the adverse effects of type 2 diabetes on cardiovascular 
morbidity and mortality, the presence of insulin resistant type 2 diabetes substantially 
increases the risk of developing atherosclerosis-related vascular disease.4 The presence of 
type 2 diabetes also significantly worsens the prognosis of most of the adverse sequelae of 
atherosclerotic arterial disease including; myocardial infarction,30 left ventricular dysfunction 
31 and peripheral vascular disease.32 Improving our understanding of mechanisms linking 
accelerated atherosclerosis and insulin signalling is thus of critical importance. Here, we 
describe the phenotype of a novel transgenic mouse with endothelium-targeted over-
expression of the human IR, generated to investigate the local and systemic consequences 
of prolonged enhancement of insulin sensitivity in the endothelium. This is the first description 
of a manipulation of the insulin signalling pathway leading to specific enhancement of insulin 
action in the endothelium; a model of particular relevance as insulin sensitisation is a strategy 
actively pursued to treat patients suffering from the cardiovascular complications of type 2 
diabetes.33 Here, we show that increased insulin sensitivity specifically in the endothelium, (a 
model of excess insulin action independent of systemic influences) at the most proximal node 
in its signalling pathway has relevant pathophysiological effects on its downstream targets.  
 
The major finding of our study is that specific and prolonged enhancement of insulin signalling 
in the endothelium in vivo establishes a positive proatherosclerotic signalling loop around the 
Akt signalling node, involving: the protein kinase Akt, the superoxide generating Nox2 
NADPH oxidase, the proline rich non-receptor tyrosine kinase, PYK2 and the endothelial NO 
synthase isoform. This circuit impacts negatively on NO actions in 2 ways: 1) by increasing 
Nox2 NADPH oxidase-derived superoxide which reacts with NO to reduce its availability. 2) 
by increasing expression of PYK2 which reduces NO production by tyrosine phosphorylation 
of eNOS, a modification shown to attenuate the activity of the enzyme. The convergence of 
these adverse pathways leads to a significant reduction in a range of downstream actions, 
fundamental to the homeostatic function of NO which allied to excess concentrations of 
endothelial cell-derived superoxide leads to a proatherosclerotic vascular environment. 
Indeed, consistent with this, hIRECO mice crossed onto an atherosclerosis-prone 
Apolipoprotein E deficient background developed significantly more atherosclerosis at the 
level of the aortic sinus and whole aorta compared to Apolipoprotein E-deficient littermates. 
Interestingly we did not see an increase in systolic blood pressure in hIRECO mice consistent 
with our findings in mice with endothelial specific insulin resistance due to expression of a 
dominant negative insulin receptor.9 These findings may reflect the relative importance of 
insulin receptors in arteries of different size. We also saw no effect on glucose homeostasis 
in hIRECO mice similar to mice with endothelial specific insulin resistance due to expression 
of a dominant negative insulin receptor and unlike mice with endothelial cell specific deletion 
of insulin receptor substrate-2 suggesting that the effect of endothelial cell insulin sensitivity 
on whole body glucose homeostasis is complex and may depend on the signalling node 
involved.34 
 
Insulin activates its intracellular signalling pathway by binding to and activating its tyrosine 
kinase receptor, which leads to activation of IR substrates (IRS). Downstream of IRS is 
phoshatidylinositol 3-kinase (PI3-K) which activates the serine/threonine kinase Akt.35 Upon 
insulin stimulation, Akt is phosphorylated by phosphoinositide dependent kinase-1 and the 
mechanistic target of rapamycin complex-2 to yield a fully activated kinase, which 
phosphorylates eNOS to increase NO synthesis in response to a range of cues, including 
mechanical shear stress and insulin.23,24 While deletion of Akt has been shown to promote 
the development of atherosclerosis36 and short-term enhancement of Akt activity has been 
shown to increase NO availability,37 unrestrained Akt activity may contribute to the 
development of atherosclerosis28 and in the setting of obesity contribute to the development 
of oxidative stress.27 Here, we demonstrate that endothelial cell over-expression of IR 
increases basal and insulin stimulated activation of Akt, which increases the activity and 
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expression of the superoxide generating enzyme Nox2 NADPH oxidase. While a link between 
PI3-K/Akt and NADPH oxidase has been proposed,38,39 this is the first study to unequivocally 
demonstrate a direct pathway between enhanced insulin sensitivity, PI3-K, Akt activation and 
Nox2 NADPH oxidase activity. During normal physiology, the NADPH oxidases generate low 
levels of reactive oxygen species in a highly regulated fashion for use in redox-dependent 
signalling.40 When the generation of reactive oxygen species exceeds their homeostatic 
threshold, a range of disorders of the human cardiovascular system may ensue.41 Enhancing 
insulin sensitivity in the endothelium not only increased basal superoxide generation, but also 
led to the ability of endothelial cells from hIRECO to generate superoxide in response to 
insulin, unlike cells from wild type mice. This insulin-mediated superoxide release was 
blunted by specific inhibitors of Nox2 and Akt.  
 
We also demonstrated increased endothelial cell expression of the cytoplasmic tyrosine 
kinase PYK2 in hIRECO mice. PYK2 is activated in response to a range of stimuli and is 
thought to be important in coupling several receptors with downstream effectors.42 Elegant 
work by Fisslthaler et al. 11 has shown that insulin and shear stress increase expression levels 
of PYK2 which in turn phosphorylates a tyrosine residue on eNOS, which leads to inhibition 
of enzyme activity and reduced NO generation. This effect, which was shown to be 
independent of reactive oxygen species and dependent on absolute expression levels of 
PYK2, has emerged as a potentially important regulator of NO generation. Here, we show in 
an in vivo model that selective enhancement of insulin sensitivity in the endothelium leads to 
increased expression of PYK2 and a concurrent increase in tyrosine phosphorylation of 
eNOS (Figure 8J). Inhibition of PYK2 reversed the detrimental effect of excess insulin 
signalling on insulin and shear stress-induced eNOS activation. We demonstrated no 
difference in phosphorylated PYK2 in hIRECO endothelial cells. However, consistent with the 
work of Fisslthaler et.al.11 an increase in the absolute levels of PYK2 expression was 
sufficient to inhibit eNOS in our system. We took this further by demonstrating that 
pharmacological blockade of Akt reduced the expression of PYK2 and we also demonstrated 
for the first time that Nox2-derived superoxide increases the expression of PYK2. This 
concomitant increase in PYK2 expression and downstream phosphorylation of eNOS at 
tyrosine residue 657 reduces eNOS activity and NO generation (Figure 8J). While other 
residues on eNOS could be phosphorylated and inhibit enzyme activity11 our data clearly 
demonstrate a key role for tyrosine residue 657 in insulin mediated adverse effects on eNOS 
activity. Consistent with our findings in mice with whole body insulin resistance we 
demonstrated an increase in basal serine phosphorylated eNOS8 which may itself limit further 
increments in eNOS activation in response to different stimuli. While our gain of function 
transgenic model generated using the hprt approach does circumvent some of the problems 
with standard transgenic models, it will be important in the future to generate and examine 
complementary gene-modified models with targeted knockout of key downstream proteins to 
enhance insulin signalling at different signalling nodes in the endothelium. 
 
Our data provides evidence of the integration of two discrete but interrelated signalling 
pathways, impacting unfavourably on NO availability. Enhancing insulin sensitivity in the 
endothelium led to excess generation of superoxide, which in a range of complementary 
assays we showed to be Nox2 NADPH oxidase-dependent. Via increased expression of 
PYK2, enhancing insulin sensitivity led to attenuation of eNOS activity in response to insulin 
and shear stress. At the centre of this lies Akt, driving the expression of both Nox2 and PYK2. 
It is important to note that type 2 diabetes is a progressive disorder and insulin hyper-
secretion can occur in healthy humans well before the onset of insulin resistant type 2 
diabetes.43 Indeed, hyperinsulinaemia is a strong independent predictor of the development 
of atherosclerosis in individuals free from diabetes.44 We have demonstrated that metabolic 
insulin resistance may precede vascular insulin resistance.45 Whether, individuals at early 
stages of the disease before the onset of hyperglycaemia or indeed individuals with type 1 
diabetes treated with high dose of insulin have evidence of the pro-atherosclerotic signalling 
circuit in the endothelium demonstrated here warrants investigation.  
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Figures and legends 
 
 
Figure 1. Characterisation of mice with endothelial cell-specific over-expression of the 
human insulin receptor (hIRECO). A) Growth (left) and organ weight (right) of hIRECO (n 
= 11) is no different to wild type (WT, n = 12) littermates. B) mRNA expression of human 
insulin receptor in heart, lungs and spleen from hIRECO and wild type littermate controls (n 
= 7-8 per group). C) mRNA expression of endogenous insulin receptor in organs from 
hIRECO and wild type littermates (n = 4). D) mRNA expression of human insulin receptor 
(hIR) in endothelial cells (PEC) and non-endothelial cells from hIRECO compared to wild type 
littermates (n = 4). E) mRNA Ve-Cadherin expression in endothelial cells from hIRECO with 
no expression in non-endothelial cells (n = 4). F) No change in mRNA expression of native 
insulin receptor expression in endothelial cells from hIRECO (n = 4). G) Western blot (left) 
showing greater insulin receptor protein expression (right) in endothelial cells from hIRECO 
(n = 6) compared to wild type littermates (n = 4). Data normalized to WT animals carried out 
in pairs. (Data presented as mean ± SEM. * denotes p<0.05; WT vs. hIRECO or hIRECO 
PEC). 
 
Figure 2. Enhanced endothelial cell insulin sensitivity in mice with endothelium 
specific over-expression of the human insulin receptor (hIRECO). Representative 
western blots shows basal levels of tyrosine-phosphorylated insulin receptor (IR-Y) with equal 
loading (60 microgram), basal eNOS and Akt phosphorylation and dose-response to  varying 
doses of insulin (50 to 150nmol/L; 15 minutes). A) Basal (left) and insulin-stimulated (right) 
tyrosine phosphorylation of insulin receptor were substantially higher in endothelial cells from 
hIRECO compared to wild type (WT) littermates (n = 4 in each group). B) Basal serine 
phosphorylation of eNOS (left) and the downstream insulin target, protein kinase B/Akt (Akt) 
(right) in endothelial cells from hIRECO (n = 7 in both groups) was enhanced in endothelial 
cells from hIRECO compared to wild type littermates. Both groups of mice were sacrificed 
and lungs were isolated at the same time and therefore, WT was set as one hundred percent 
as comparison to hIRECO. C) Dose response to insulin in endothelial cells demonstrating 
increased sensitivity to insulin-mediated serine phosphorylation of Akt in endothelial cells 
from hIRECO (n = 10) compared to wild type littermates (n = 7) (Data presented as mean ± 
SEM. * denotes P<0.05 vs. WT control, † denotes p<0.05 vs. hIRECO control). 
 
Figure 3. Metabolic function and systolic blood pressure in mice with endothelial cell 
specific over-expression of the human insulin receptor (hIRECO). A) No difference in 
fasting glucose between hIRECO (n = 7) and wild type littermates (WT, n = 9). B) No 
difference in fasting insulin between hIRECO and wild type littermates. C) No difference in 
systolic blood pressure between hIRECO (n = 6) and wild type littermates (n = 7). D) No 
difference in glucose tolerance tests between hIRECO (n = 7) and wild type littermates (n = 
9). E) No difference in insulin tolerance tests between hIRECO (n = 7) and wild type 
littermates (n = 8). F) No difference in triglycerides between hIRECO (n = 8) and wild type 
littermates (n = 6). G) No difference in free fatty acids between hIRECO (n = 7) and wild type 
littermates (n = 6). Data presented as mean ± SEM. 
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Figure 4. Mice with endothelial cell specific over-expression of the human insulin 
receptor (hIRECO) have blunted responses to the endothelium NO dependent 
vasodilator acetylcholine and reduced NO bioavailability in response to isometric 
tension. A) Both groups of mice were harvested, isolated and stimulated or studied at the 
same time in the same conditions. Acetylcholine-mediated vasorelaxation of aortic rings from 
hIRECO mice is blunted compared to wild type littermates (WT) (n = 6). B) No significant 
differences were observed in phenylephrine-mediated constriction of aortic rings from 
hIRECO compared to wild type littermates. (n = 5 in each group). C) No significant differences 
were observed in sodium nitroprusside responses of aortic rings from hIRECO compared to 
wild type littermates. (n = 6 in each group). D) Reduced constriction to L-NMMA (0.1mmol/L; 
30 minutes) in hIRECO indicative of reduced nitric oxide bioavailability in response to 
isometric tension compared to wild type littermates (n = 6 in each group). E) Effect of insulin 
(4 mU/ml; 2 hours) on PE-mediated vasoconstriction is blunted in hIRECO compared to wild 
type littermates (n = 6 in each group). F) Direct insulin-mediated vasorelaxation is blunted in 
hIRECO compared to WT (left) (n = 7 in each group). L-NMMA significantly blunted insulin-
mediated vasodilatation (right) (n = 7 in each group). G) Insulin-stimulated eNOS activity in 
endothelial cells was significantly blunted and was lower in endothelial cells from hIRECO (n 
= 7) compared to WT (n = 4). Insulin-stimulated eNOS activity of each type of mouse was 
compared against its own unstimulated control, set as one hundred percent. (Insulin 
150nmol/L; 45 minutes). H) Representative western blots shows shear stress-induced Akt 
and eNOS phosphorylation. Shear stress-mediated serine-473 phosphorylation of Akt (12 
dyne/cm2; 10 minutes) was not different between both groups of mice (n = 8-9). I) In hIRECO 
endothelial cells shear stress-mediated serine-1177 phosphorylation of eNOS was blunted 
(n = 4) when compared to WT (n = 6). (Data presented as mean ± SEM. In western blot, TG 
denotes hIRECO. * P<0.05 vs. unstimulated or uninhibited controls). 
 
Figure 5. Role of oxidative stress in reduced NO bioavailability in mice with endothelial 
cell specific over-expression of the human insulin receptor (hIRECO). A) Restoration of 
acetylcholine-mediated vasorelaxation of aortic rings from hIRECO (n = 7 in each group) after 
exposure of rings to the superoxide dismutase mimetic, MnTmPyP (10 micromol/L, 30 
minutes). B) Acetylcholine-mediated vasorelaxation of aortic rings from hIRECO (n = 8 in 
each group) after exposure to the Nox2 NADPH oxidase inhibitor, gp91ds-tat (gp;10 
micromol/L; 30 minutes) was restored to wild type  littermates’ (WT) level. C) NADPH-
dependent superoxide generation in endothelial cells from hIRECO mice is increased in 
lucigenin-enhanced chemiluminescence assay (n = 10 in each group). D) Increased 
expression of Nox2 NADPH oxidase in endothelial cells from hIRECO (n = 7). E) left 
Endothelial cells from hIRECO treated with Nox2 inhibitor, gp91ds-tat (gptat; 10 micromol/L; 
60 minutes) have reduced superoxide production by chemiluminescence analysis of 
superoxide generation E) centre gp91ds-tat inhibitable superoxide production was 
significantly greater in hIRECO than WT by DHE HPLC-based assay, presented as 
percentage difference from uninhibited control (n = 10 in each group) E) right Amplex Red 
quantification of hydrogen peroxide showed increased levels of hydrogen peroxide in 
hIRECO cells compared to WT (n = 5 in each group). F) Chronic treatment of hIRECO with 
the Nox2 inhibitor gp91ds-tat or scrambled (Scr) control for 28 days had no effect on body 
mass (n = 8 in each group). G) Chronic treatment of hIRECO with the Nox2 inhibitor, gp91ds-
tat or scrambled (Scr) control for 28 days had no effect on glucose (left) or insulin tolerance 
(right) (n = 6 in each group). H) Chronic treatment of hIRECO with the Nox2 inhibitor 
gp91dstat (10 micromol/L) for 28 days increased maximal relaxation of aortic rings to 
acetylcholine compared to scrambled (Scr) control (n = 6 in each group). (Data presented as 
mean ± SEM. * denotes P<0.05 WT vs. hIRECO, † denotes P<0.05 hIRECO vs. 
hIRECO+gp91ds-tat).  
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Figure 6. Insulin mediated generation of superoxide is enhanced in endothelial cells 
from mice with endothelial cell specific over-expression of the human insulin receptor 
(hIRECO) and is PI3K- and Akt-dependent. Increased tyrosine phosphorylated eNOS 
and increased expression of proline rich tyrosine kinase (PYK2) in hIRECO mice. A) 
Role of PI3-kinase in excess superoxide production in endothelial cells from hIRECO was 
confirmed by the PI3-kinase specific inhibitor Wortmannin (WM, 50 nanomol/L; 30 minutes) 
and a complementary the PI3-kinase specific inhibitor B) LY294002 (LY, 5 micromol/L; 30 
minutes), both of which reduced superoxide production in hIRECO endothelial cells to a 
greater extent than wild type (n = 5). C) The Akt inhibitor MK-2206 (MK, 10 micromol/L; 3 
hours) reduced superoxide generation from hIRECO endothelial cells (n = 4-5). D) Insulin-
stimulated (Ins, 150 nmol/L; 3 hours) superoxide release was reduced in endothelial cells 
from hIRECO by the inhibitor of Nox2 NADPH oxidase gp91ds-tat (gptat, 10 micromol/L; 60 
minutes) and Akt inhibitor, MK-2206 (MK; 10micromol/L; 60 minutes) (n = 10). Representative 
blots showing eNOS-pY657, eNOS-pS1177 (eNOS-p), PYK2 expressions in various 
experimental conditions, as stated on the far left panel. E) (left) Increased tyrosine 657-
phosphorylated eNOS in hIRECO endothelial cells compared to wild type littermates (n = 5), 
(right) Inhibition of NOX2 by gp91ds-tat led to reduced tyrosine-657 phosphorylation of 
eNOS. F) Proline-rich tyrosine kinase 2 (PYK2) expression is increased in hIRECO 
endothelial cells (n = 4). G) Gene silencing of PYK2 in hIRECO endothelial cells using siRNA 
resulted in approximately 50% knockdown compared to scrambled (Scr siRNA) siRNA control 
(n = 5). H) Insulin-stimulated eNOS activity was reversed in hIRECO endothelial cells upon 
PYK2 siRNA (siPYK2) knockdown (n = 5). I) Shear stress-induced (Shear) eNOS 
phosphorylation was restored in hIRECO endothelial cells following PYK2 siRNA knockdown 
(n = 6). (Data presented as mean ± SEM. * denotes P<0.05 WT vs hIRECO or Control vs 
WM, LY, MK, Insulin, gptat, PYK2 siRNA, † denotes P<0.05 (hIRECO+Insulin/shear stress) 
vs. (hIRECO + PYK2 siRNA+Insulin/shear stress), hIRECO Ins vs. (hIRECO MK+Ins), †† 
denotes P<0.05 hIRECO+Ins vs. hIRECO gptat+Ins. 
 
Figure 7. Crosstalk between Nox2 and PYK2 in endothelial cells from mice with 
endothelial cell specific over-expression of the human insulin receptor (hIRECO). Left 
panel shows representative blots for PYK2 phosphorylation (PYK2-p) PYK2, and beta-actin 
loading control; eNOS and Nox2 in various experimental conditions studied. A) Inhibiting 
basal Nox2 activity with gp91-dstat (gptat) and inhibition of Akt by MK-2206 (MK, 10 mol/L; 8 
hours) in endothelial cells from hIRECO reduced PYK2 expression (n = 5). B) Reducing basal 
Nox2 expression with siRNA in hIRECO endothelial cells also reduced PYK2 expression. C) 
Knock-down of PYK2 in hIRECO (hIR) endothelial cells using siRNA reduced Nox2 
expression (n=4-5). D) Knockdown of PYK2 (PYK2) and not NOX2 (siNOX2) using siRNA in 
endothelial cells of hIRECO significantly enhanced insulin-stimulated (Ins, 150 nanomol/L; 
15 minutes) serine-phosphorylation of eNOS (n=6). Percentage phosphorylation was 
assessed by normalizing against unstimulated control of each mouse. (Data presented as 
mean ± SEM. * denotes P<0.05 wild type (WT) vs hIRECO, † denotes P<0.05 hIRECO vs. 
hIRECO siRNA PYK2, hIRECO vs. hIRECO siRNA-NOX2, hIRECO vs. hIR siRNA PYK2, 
hIRECO Ins vs. hIRECO PYK2+Ins). 
 
Figure 8. Endothelial-specific over-expression of human insulin receptor mice 
(hIRECO) have increased atherosclerosis when crossed onto an ApoE-deficient 
background (ApoE-/-/hIRECO). A) No difference in body weight after 12 weeks western diet 
in ApoE-/-/hIRECO compared to ApoE-/- littermates. B) Systolic blood pressure after 12 weeks 
western diet in ApoE-/-/hIRECO compared to ApoE-/- littermates C)No difference in fasting 
cholesterol in ApoE-/-/hIRECO compared to ApoE-/- littermates. . D) No difference in fasting 
triglycerides in ApoE-/-/hIRECO compared to ApoE-/- littermates. E) No difference in fasting 
blood glucose levels or F) No difference in glucose tolerance or G) insulin tolerance testing 
after 12 weeks western diet in ApoE-/-/hIRECO compared to ApoE-/- littermates H) Increased 
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plaque development in the thoracic aorta in ApoE-/-/hIRECO mice compared to ApoE-/- 
littermates. I) Increased plaque development at the level of the aortic sinus in ApoE-/-/hIRECO 
mice compared to ApoE-/- littermates J) Proposed mechanism of downstream effects of 
increased insulin sensitivity in the endothelium. (Data presented as mean ± SEM. n = 15 mice 
per group, * denotes P<0.05, ApoE-/- vs. ApoE-/-/hIRECO; + denotes stimulatory effect,- 
denotes inhibitory effect).  
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Novelty and Significance 
 
What is known? 
 
 Insulin binds to its tyrosine kinase receptor to activate downstream signalling molecules including 
Akt/PKB leading to activation of endothelial nitric oxide synthase (eNOS) which stimulates production 
of the antiatherosclerotic signalling radical nitric oxide. 
 
 Resistance to the action of insulin in the endothelium a well-established feature of type 2 diabetes 
leads to a proatherosclerotic imbalance between nitric oxide and superoxide. 
 
 Mice with endothelium specific insulin resistance develop accelerated atherosclerosis. 
 
What new information does this article contribute? 
 
 Over expressing insulin receptors in the endothelium increases insulin mediated activation of Akt. 
 
 Over expressing insulin receptors in the endothelium leads to PYK2 mediated inhibition of eNOS and 
increased generation of superoxide, the enzymatic source of which was the Nox 2 isoform of NADPH 
oxidase. 
 
 Over expressing insulin receptors in the endothelium accelerated the development of atherosclerosis 
in hyperlipidaemic apolipoprotein E-deficient mice.  
 
Type 2 diabetes is associated with whole body and endothelial cell insulin resistance. While the 
proatherosclerotic effect of endothelial cell insulin resistance is well established, the effect of enhancing 
insulin sensitivity in the endothelium remains unclear. To examine the effect of selective enhancement of 
insulin sensitivity in the endothelium we generated transgenic mice with endothelium specific over expression 
of insulin receptors.  
 
In mice with endothelium specific over expression of insulin receptors both insulin and acetylcholine mediated 
vasorelaxation of aortic rings was blunted. The impaired relaxation in response to acetylcholine was restored 
by the Nox2 NADPH oxidase (Nox2) specific inhibitor gp91dstat. Further probing the mechanisms underlying 
these findings we showed that insulin mediated Akt phosphorylation in endothelial cells was enhanced which 
increased Nox2 generated superoxide. In addition to this proatherosclerotic perturbation, we also 
demonstrated an Akt and Nox2 dependent increase in expression of the non-receptor tyrosine kinase PYK2 
which fed back to increase Nox2 expression and downstream led to inhibitory tyrosine phosphorylation of 
eNOS. 
 
This work reveals a previously unrecognised insulin activated proatherosclerotic signalling circuit involving 
Nox2, Akt, PYK2 and eNOS. Increasing insulin sensitivity in the endothelium activates and amplifies this loop 
to drive the development of atherosclerosis.  
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SUPPLEMENTAL MATERIALS 
Selective enhancement of insulin sensitivity in the endothelium in vivo reveals a novel 
proatherosclerotic signalling loop. 
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SUPPLEMENTAL MATERIALS 
 
Detailed and Extended Methods 
 
Mice over expressing the human insulin receptor specific to the endothelium.  
To overcome the limitations seen in standard transgenics we used the Hypoxanthine Phophoribosyl 
transferase (Hprt) targeting system1 applying ‘Quick Knock-inTM’ (GenOway) technology to generate 
genetically modified embryonic stem (ES) cells. This approach uses homologous recombination to 
target a single copy of a transgene (in this case the human IR) driven by a promoter (in this case the 
Tie2 promoter) into the Hprt locus on the X chromosome (Supplemental Figure IA). 
As previously described2 the model was developed with E15Tg2a (E14) cells derived from the strain 
129P2/OiaHsd (12901a). In E14 cells, 35kb of the Hprt gene encompassing the 5’ UTR up to intron 
2 is deleted. The Hprt gene encodes a constitutively expressed housekeeping enzyme involved in 
purine synthesis from the degradation products of nucleotide bases (salvage pathway). Cells 
normally synthesise purines by the salvage and de-novo pathways. In Hprt deleted cell lines, only 
the de-novo pathway is functional enabling the cells to grow in classical medium. However, in the 
presence of the aminopterin drug the de-novo pathway is blocked. As a result Hprt deleted cells die 
in media called HAT (containing hypoxanthine, aminopterin and thymidine substrates). The targeted 
insertion of a transgenic cassette in E14 ES cells with a functional Hprt gene rescues these cells, 
which can then be selected using HAT media to identify ES cells showing the correct targeting event. 
Thus ES cells with the correct insertion can be selected by virtue of their expression of Hprt and the 
resultant ability to grow in HAT medium. Numerous studies have shown that the functional properties 
of the Hprt locus protect transgenic constructs inserted in this region against gene silencing and 
positional or methylation effects. Furthermore, tissue-specific promoters including Tie2 inserted3 into 
the Hprt locus maintains their expression properties. This sequence has been shown confer uniform 
and high level of expression of Lac Z reporter gene in endothelial cells in vivo. 
 
Vector construction. Endothelial cell-specific transgene expression was achieved using the mouse 
Tie2 promoter and intronic enhancer as previously described. In order to reduce the size of 
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transgene the minimal-enhancer sequence (core-enhancer) was inserted into the final construct. 
This sequence has been shown confer uniform and high level of expression of Lac Z reporter gene 
in endothelial cells in vivo. The targeting vector was obtained by inserting human IR cDNA (a kind 
gift from Dr M Quon NIH Bethesda USA) into the pHHNS plasmid comprising the murine Tie2 
promoter, LacZ cDNA and SV40 polyA signal and a 10-kb intronic enhancer from the murine Tie2. 
The targeting vector was obtained by inserting human IR cDNA (a kind gift from Dr M Quon NIH 
Bethesda USA) into the pHHNS plasmid comprising the murine Tie2 promoter, LacZ cDNA4 and 
SV40 polyA signal and a 10-kb intronic enhancer2 from the murine Tie2. The final transgenic vector 
consisting of Tie2 promoter, human IR, polyadenylation site and core-enhancer was then inserted 
into the Hprt targeting vector by a gateway reaction between the transgenic vector and the Hprt 
targeting vector. The final targeting vector had the following features; 1) Isogenic with E14 ES cells 
favouring homologous recombination, 2) Symmetrical homology arms (5’ short arms-SA: 3.8kb, 3’ 
long arm –LA: 3.7kb), 3) Transgenic cassette expressing the human IR cDNA under control of the 
short form of the Tie2 promoter, 4) Wild type Hprt sequences to reconstitute the Hprt gene in the 
E14 ES cells. In ES cells, this process was highly successful with 3 clones selected for blastocyst 
injection. The 5’ and 3’ targeting events were unambiguously confirmed by Southern blot analysis. 
These 3 ES clones were expanded and genetically manipulated agouti ES cells were then injected 
into C57BL/6J derived blastocysts that were then implanted into the uteri of recipient females. 
 
Breeding of Chimeras and generation of F1 mice heterozygous for the human insulin 
receptor. Highly chimeric males (displaying 100% chimerism) generated by blastocyst injection of 
ES clones were mated with 2 wild type C57BL/6J female mice, to examine whether the targeted ES 
cells contributed to the germ layer. To assess whether ES cells have contributed to the germ layer 
of chimeras, mouse coat colour markers are used. The ES cells used to develop the model were 
originally derived from a 129 strain of mice which have an agouti coat colour. This marker is dominant 
over the black coat of C57BL/6 mice. Therefore, mating of the chimeras with C57BL/6J mice yields 
agouti coloured pups when the ES cells have contributed to the germ layer. Agouti F1 females were 
genotyped by Southern blot (Supplemental Figure IB). Southern blot validated the correct 
heterozygous status of tested F1 females, by detecting the 15.2 kb sized AvrII fragment of the 
C57BL/6 Hprt wild type allele and the 9.8kb sized AvrII fragment of the reconstituted Hprt allele 
(females #2, #-4, #6, #7, (Supplemental Figure IB). Genotyping protocol validated the multiple copies 
of transgene (Supplemental Figure IC). Two of the F1 females were backcrossed for at least 10 
generations into a C57BL/6J background and genotyped (Supplemental Figure ID) before 
commencing experiments. 
All experiments were carried out comparing with wild type littermate controls. Genotyping PCR 
primer sequence (5’ to 3’): Primer 1, ACGTCAGTAGTCATAGGAACTGCGGTCG and Primer 2, 
TGCCTTGATTCACCAGATGCTGAGG. 
High performance liquid chromatographic measurement of conversion of dihydroethidium to 
oxyethidium. Aortic segments were incubated with scrambled peptide or the Nox2 specific inhibitor, 
gp91-dstat for 30 minutes in KREBS buffer and then washed twice with PBS before incubating in 
PBS/DHE at a final concentration of 100 μmol/L for 30 min. Cells were washed thrice with cold PBS, 
harvested in cold methanol/HCl (0.5 ml/well), vortexed vigorously, centrifuged (12,000 g for 10 min 
at 4°C), and supernatants recovered for analysis. Pellets were stored at –20°C in the dark until 
analysis. Samples were injected (30μL), into an HPLC system (Shimadzu), equipped with a 
photodiode array (SPD-M10AVP) and fluorescence (RF-10AXL) detectors. Chromatographic 
separation was carried out in a C18-Kromosil column (4.6 x 250 mm, 5 μm particle size) and DHE 
monitored by ultraviolet absorption at 245 nm and EOH and ethidium by fluorescence detection 
(excitation 510 nm and emission 595 nm). Quantification is performed by comparison of peak signal 
between the samples and standard solutions under identical chromatographic conditions25. DHE-
derived products are expressed as ratios of ethidium generated per DHE consumed (ethidium/DHE) 
and normalized against total weight of tissue. Data expressed as gp91ds-tat-inhibitable component 
of superoxide.  
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Amplex red assay for hydrogen peroxide in aorta. Freshly harvested aortas were collected into 
a modified Krebs-HEPES buffer,  containing 20 mM HEPES, 119 mM NaCl, 4.6 mM KCl, 1 mM 
MgSO4.7H2O, 0.15 mM Na2HPO4, 0.4 mM KH2PO4, 5 mM NaHCO3, 1.2 mM CaCl2 and 5.5 mM 
glucose, pH 7.4. The aortas were cleaned of peripheral adipose tissue and divided in about 2mm 
aortic rings.2 Half of the aortic rings were incubated in 50µL of modified Krebs-HEPES buffer and 
the remaining aortic rings were incubated in 50µL of modified Krebs-HEPES buffer with 1250 U/mL 
catalase (free from tymol) for 1h at 37°C. Fifty microlitres of freshly-prepared 100 μM Amplex Red 
reagent with 0.2U/mL HRP was added to the samples and incubated for 1 hour at 37°C, protected 
from light. The aortic rings were removed from the samples and fluorescence was measured on 
VarioSkan (Thermo Scientific) plate reader (excitation 530 nm and emission 590 nm). The average 
readings with catalase were subtracted from average readings without catalase, and the value was 
used as input into an H2O2 standard curve. The H2O2 standard curve was prepared in the same plate 
simultaneously, with the tissues and was used to determine H2O2 concentration released in the 
samples. Weight of blotted dry tissue was used for normalization. 
 
Pulmonary endothelial cell isolation and culture. Lungs were harvested, washed, finely minced 
and digested in HBSS containing 0.18U/ml collagenase type 2 (Worthington, USA) and for 45 
minutes at 37°C5. The digested tissue was filtered through a 70μm cell strainer and centrifuged at 
1200 rpm for 5 minutes. The cell pellet was washed with PBS/0.2% BSA, centrifuged, resuspended 
in 100µl of PBS/0.2%FCS and incubated with 1 x 106 CD146-Ab-coated beads at 4°C for 15 
minutes1,6. Bead-bound cells were separated from non-bead bound cells using a magnetic MS 
Column (Miltenyi Biotechnology). Bead-bound (CD146-positive) and non-bead-bound cells were 
resuspended in 2 ml Endothelial growth medium–MV2 (PromoCell, Heidelberg, Germany) 
supplemented with hEGF, hydrocortisone, VEGF, hFGF-B, R3-IGF-1, ascorbic acid, gentamicin, 
amphotericin-B and 5% FCS and plated out. Only the endothelial cell population tested positive for 
a range of endothelial markers including eNOS, Tie2, ve-cadherin, vWF and CD102 protein 
measured using immunoblotting. 
 
Characterisation of isolated pulmonary endothelial cells using DiI-Ac-LDL 
 
The endothelial phenotype of PEC was corroborated by demonstrating uptake of acetylated low-
density lipoprotein cholesterol (Ac-LDL). Confluent PEC were incubated in standard culture medium 
containing 10ug/ml DiI-conjugated Ac-LDL (Molecular Probes, ThermoFisher Scientific) for one hour, 
prior to washing with PBS and fixing with 4% paraformaldehyde in PBS. Imaging was performed 
using an Olympus CKX-41 microscope using a red fluorescence emission filter. No fluorescence 
was detected in PEC not exposed to DiI-conjugated Ac-LDL. 
 
Cell lysis, Immunoblotting. Primary endothelial cells were lysed in extraction buffer containing 
50mM HEPES, 120mM NaCl, 1mM MgCl2, 1mM CaCl2, 10mM NaP2O7, 20mM NaF, 1mM EDTA, 
10% glycerol, 1% NP40, 2mM sodium orthovanadate, 0.5µg/ml leupeptin, 0.2mM PMSF, and 
0.5µg/ml aprotinin. Insulin-stimulated endothelial cells were serum-deprived overnight with 1% FCS-
containing endothelial cell media before stimulation and harvesting in lysis buffer for western blot 
analysis6. Cell extracts were sonicated in an ice-bath and centrifuged for 15 minutes at 13000 rpm, 
before protein measurements were carried out by BCA assay (Pierce Protein Quantification Kit) 
using the supernatant. Equal amounts of cellular protein were resolved on SDS polyacrylamide gels 
(Invitrogen) and transferred to polyvinylidine difluoride membranes. Immunoblotting was carried out 
with indicated primary antibodies, diluted as necessary in 5% BSA-TBST buffer. Blots were 
incubated with appropriate HRP-conjugated secondary antibodies and developed with enhanced 
chemiluminescence (Millipore). Sixty micrograms of total cell lysate was used for 
immunoprecipitation and thirty micrograms for western blotting with indicated antibodies: IR beta 
(C19) and β-Actin, (Santa Cruz Biotechnology), phospho-tyrosine, (pY4G10, Millipore), Nox2, eNOS, 
phospho-eNOS (BD Biosciences), PYK2, phospho-PYK2, Akt and phospho-Akt, (Cell Signalling), 
and phospho-tyrosine 657 (ECM Biosciences) and Protein A-Dynabeads (Invitrogen) for 20 minutes 
at room temperature. Akt inhibitor, MK-2206 10 micromol/L was from SeleckChem. Immunoblots 
were scanned on a Syngene Gel Documentation System and bands quantified using Syngene 
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Genetools Image Analysis software. Where bar charts depict percentage of control or wild type, we 
carried out all experiments for the two groups of mice (wild type and hIRECO) in pairs using the 
same conditions; from harvesting organs, isolating cells and stimulation of insulin or various 
inhibitors/siRNA and therefore, set its own wild type or serum-deprived control wells as hundred 
percent. When responses to insulin or inhibitors were analysed, the experiments were serum-
deprived in 0.5% serum containing medium without supplements overnight before carrying out 
stimulation and harvesting. Chronic inhibition in cells to analyse protein expression was been 
performed in full growth medium and inhibitors incubated for 8 hours prior to harvest. 
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